New GSK To Leave Flagship HQ After Consumer Health Split
Will Depart Landmark HQ
Company follows US office downsizing with similar plans for its global headquarters, once consumer health spin-out is complete in 2022.
You may also be interested in...
A second activist investor has called for GSK to consider replacing Emma Walmsley as CEO
, and has underlined competitive threats to a key pipeline candidate.
Once the consumer health division is spun out in mid-2022, a leaner ‘new GSK’ must set about delivering on its promising pipeline – and proving its skeptics wrong.
GSK’s PD-1 inhibitor will not be able to make up much ground on Keytruda, but new studies suggest it is a match for the market-leading PD-1 inhibitors.